Thomas A. Marsland, MD
Petaluma, CA 94954
Providence Medical Group Petaluma - Cancer Center
110 Lynch Creek Way, Suite A, Petaluma, CA 94954
Are you covered?
Check to see if your insurance is covered by this provider.
About Thomas A. Marsland
Dr. Marsland has over 30 years of experience in treating patients with hematologic and oncologic issues. He believes the doctor-patient relationship is a team with both parties involved in determining the best plan of care. He actively supports the St. Joseph Clinical Research Program. Dr. Marsland recently moved from Florida to Northern California (April 2017) with his wife to be near his family of three daughters and his new grandson. His hobbies include fine dining and good wine. The Sonoma/Napa County area are a great fit.
PUBLICATIONS/ PRESENTATIONS
I. Biomarker Analyses From a Randomized, Placebo-Controlled, Phase Illb Trial Comparing Bevacizumab With or Without Erlotinib as Maintenance Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer, May' 13. Submission to Journal of Clinical Oncology.
2. Atlas: Randomized, Double-Blind, Placebo-Controlled, Phase ll!B Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy With Bevacizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer, 2012. Johnson, B., Kabbinavar, F., Fehrenbacher, L., Hainsworth, J., Kasubhai, S., Kresse!, B., Lin, Chin-Yu., Marsland, T., Patel, T., Polikoff, J., Rubin, M., White, L., Chin-Hsin Yang, J., Bowden, C., Miller, V. Journal of Clinical Oncology 2012.
3. Marsland, Lung Cancer Screening: A New Era Oncology, February 2012.
4. Marsland, Reducing Cancer Costs & Improving Quality through Collaboration with payers, Journal of Oncology Practice, Sept. 2010.
5. S.L. Wong, P. Mamgu, T. Chati, G. Dodd, G. Dorfman, C. Emg, T. Marsland. et al. American Society of Clinical Oncology, 2009 Clinical Epredesine Review of RFA of Hepatic met Journal of Clinical Oncology. 28:493-508, 2010.
6. B. McAnemy, T. Marsland, K. King; News and Notes from 2009 CAC. Meeting Medical Necessity, off label News and Notes From the 2009 Carrier Advisory Committee Meeting: Medical Necessity, Off-Label Chemotherapy, and More, Journal of Oncology Practices; 301-304, Nov. 09.
7, Matuzumab in second line treatment for patients with Stage III & IV NSCLC, J. Thorac One. '09.
8. J.A. Bubis, I.A. Marsland, K.M, Justice, D. Edwards. Features of patients (pts) with metastatic breast cancer
(MBC) and a circulating tumor cell count (CTCC) of 0. Accepted for poster discussions, San Antonio Breast Cancer Symposium, 2007. Abstract l 06.
9. C.P. Belani, S. Ramalingam, M. Schreede, R. Steis, R. Guidice, T. Marsland, B. Butler. Phase II study of Cetuximab in combination with Carboplatin and Docetaxel for patients with advanced/Metastatic non small cell lung cancer (NSCLC). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol. 25, No. 18S (June 20 Supplement), 2007:764.
10. Gray, J., Spigel, D., Hainsworth, J., Vazquez, E., Peyton, J., Raefsky, E., Malik, R., Marsland, T., Waples, J., Greco, F. Maintenance gefitnib (0) after chemo radiotherapy (CRT) in patients (pts) with unresectable stage IIIA/B non-small cell lung cancer (NSCLC): A Phase II trial of Minnie Pearl Cancer Research Network. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I, Vol. 24, No. 18S (June Supplement), 2006: 7188.
11. Shipley, D., Hainsworth, J., Spigel, D., Gray, J., Barton, J., Switzer, A., Nicolau, M,, Marsland, T., Jospeh, G., Greco, F., Topotecan: Weekly Intravenous (IV) Schedule Similar to Standard 5-Day IV.Schedule as Second-Line Therapy for Relapsed Small Cell Lung Cancer (SCLC) -A Minnie Pearl Cancer Research Network Phase II Trial. Journal of Clinical Oncology 2006 ASCO Annual Meeting Proceedings Part I. Vol. 24, No. 18S (June 20 Supplement), 2006: 7083.
12. Result ofa Phase II trial ofGencitabine in Patients with Non-Small Cell Lung Cancer and Performance Status of Two. Clinical Lung Cancer Trials, Volume 6 #4, 2005.
13. I.A, Marsland, D.H. Garfield, M.M. Khan, R.M. Look, K.A. Boehm, L.A. Smar. Sequential vs Concurrent Paclitaxel and Carboplatin for treatment of advanced non-small cell lung cancer (ANSCLC) in elderly patients with poor performance status: results of two Phase II, multicenter trials. US Oncology Research Inc., 2004.
14. Neubauer, M., Reynolds, C., Joppert, M., Whittaker, T,, Ahmad, Y., Ghaddar, H., Marsland, T., Asmar, L., US Oncology Research, Inc,, Houston, TX. Preliminary results of a phase II trial utilizing Gemcitabine in patients with advanced non-small cell lung cancer and a performance status 2. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceeding (Post Meeting Edition). Volume 22, No I 4S (July Supplement), 2004: 1721.
I5. Sequential Verses Concurrent Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small Cell Lung Cancer in Elderly and Patients with Poor Performance Status. Result of our Phase II Trial Lung Cancer, June, 2004.
16. Phase II Trial Utilizing Oemcitabine in Patients with Advanced Non-Small Cell Lung Cancer and a Performance Status 2, American Society of Clinical Oncology Abstracts, 2004, #7121 Poster Presentation.
17. Liposomal Doxorubicin as a Single Agent Treatment of Low-Grade Non- Hodgkin's, Vol. 3 #4, 2003.
18. Phase II Study of First-line Chemotherapy Using CT-2103 in Patients with NSCLC who are Less than or Equal to 70 years of Age or who have PS= 2. Abstract, 2002.
19. Joppert, M., Garfield, D., Gregurich, M., Nemunaitis, J,, Marsland, T., Khandelwal, P., Asmar, L. US Oncology, Houston, TX. First-line Chemotherapy with Topotecan and Gemcitabine for Patients with Advanced Non-Small Cell Lung Cancer. American Society of Clinical Oncology Abstracts, 2002, #2671.
20. Phase II Study if Sequential Chemo-Therapy followed by Maintenance Therapy with Oral Orzel in Patients with Stage IIIB & IV Non-Small Cell Lung Cancer. Abstract
2I. U.S. Oncology Clinical Research the Role and Function of the Lung Committee. Abstract Second. World Conference on Clinical Research for Lung Cancer, 2002.
22. Garbo, L., Marsland, T., Garfield, D., Khan, M., Asmar, L. US Oncology, Houston, TX., A phase II Study of Weekly Paclitaxel (Taxol®) In Stage IIIB, IV, or Relapsed After Local Therapy, Non-Small Cell Lung Cancer
(NSCLC) Patients with a Performance Status of2 and/ or 70 Years of Age, with (Paraplatin®) Administered at Disease Progression. ASCO, 2001. Abstract #2821.
23. Phase II Study of Weekly Taxol and Paraplatin in Stage IIIB & IV NSCLC in patients who are Less Than Equal to Age 70 and a Male with PS II. ASCO Abstract, 2001. #2819.
24. Liposomal Doxorubicin as a Single Agent Treatment of Low-Grade Non-Hodgkin's. American Society Hematology Abstract, 2000.
25. Estrogen Receptor Status and Response to Advance Breast Cancer. CANCER, 46;2919-2921, 1980.
26. Estrogen Receptor Status and Response Chemotherapy. ASCO Abstracts, 1979.
RESEARCH
- Over twenty-six years clinical research experience, including industry and network trials.
CLINICAL REVIEW
ASCO Self Evaluation Program
- 2007 Lung Cancer Chapter
- 2009 Presentation & Screening Chapter
- 2011 Presentation & Screening Chapter
- 2014 Preventions and Screening Chapter
ORAL PRESENTATIONS
Veridex: Role of Circulation Tumor Cells
- 2008 Houston, TX
- 2009 Huntsville, AL
- 2009 Huntsville, IN
Cost of Healthcare with ION
- 2008 Phoenix, AZ
- 2009 Houston, TX
Healthcare Economics (Con/era Group)
- 2007 Charlotte, NC
- 2008 Charlotte, NC
- 2009 Princeton, NJ
2012 Stress of Community Oncology Practices
2012 Value Based Cancer Care Conferences
2013 Value Based Cancer Care Conferences
Temple University Hospital
1974
Temple University Hospital
Internal Medicine
1975
Temple University Hospital
Internal Medicine
1977
Tufts - New England Medical Ctenter
Medical Oncology
1979
University Of Massachusetts Medical Center
Hematology
1980
American Society of Clinical Oncology, Duval County Medical Society, Clay County Medical Society, Conquer Cancer Foundation, Florida Society of Clinical Oncology, Thompson-Reuter 's, Oncology (Journal) Editorial Board, ACCC Membership Committee, InteCare, Vantage Health Plan, Clay Independent Practice Associates, American Oncology Resource, Orange Park Medical Center
- American Board of Internal Medicine, Medical Oncology
- American Board of Internal Medicine, Internal Medicine
Providence Medical Network
Petaluma Valley Hospital
Santa Rosa Memorial Hospital
Community Reviews
At Providence, we're dedicated to providing you quality, personalized health care. We are constantly striving to optimize your experience.
As part of ensuring you have a positive experience with Providence, our online provider directory includes ratings and patient comments for select providers. More about our survey.
Great Dr
Providence Patient
Excellent
Providence Patient
Somehow bad
Providence Patient
When I checked that nobody in the office called to review test results that is true. However I always get MyChart alerts and at the visit Dr Marsland always discusses the results.
Providence Patient
Dr. Marsland is very good. He knows my history, he provides updates on bloodwork I have done, he's very thorough and empathetic. An excellent oncologist!
Providence Patient
Great service and caring for my medical needs
Providence Patient